PAZOPANIB HYDROCHLORIDE (pazopanib) by Teva is multi-tyrosine kinase inhibitor of vascular endothelial growth factor receptor (vegfr)-1, vegfr-2, vegfr-3, platelet-derived growth factor receptor (pdgfr)-α and -β, fibroblast growth factor receptor (fgfr)-1 and -3, cytokine receptor (kit), interleukin-2 receptor-inducible t-cell kinase (itk), lymphocyte-specific protein tyrosine kinase (lck), and transmembrane glycoprotein receptor tyrosine kinase (c-fms). First approved in 2023.
Drug data last refreshed 18h ago
multi-tyrosine kinase inhibitor of vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2, VEGFR-3, platelet-derived growth factor receptor (PDGFR)-α and -β, fibroblast growth factor receptor (FGFR)-1 and -3, cytokine receptor (Kit), interleukin-2 receptor-inducible T-cell kinase (Itk),…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Spartalizumab and Low-dose PAzopanib in Refractory or Relapsed Solid TumOrs of Pediatric and Adults
HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas
Pazopanib Vs. Pazopanib Plus Gemcitabine
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery
Worked on PAZOPANIB HYDROCHLORIDE at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.